Journal: bioRxiv
Article Title: Intracellular Delivery of Full-Length Antibodies via Poly-L-lysine-Coated PEG–PLGA Polymersomes Enables Non-invasive Pulmonary Immunotherapy
doi: 10.1101/2025.09.16.676558
Figure Lengend Snippet: (A) Schematic of experimental design using primary human lung fibroblasts. (B) Quantification of IL-1β levels in culture supernatants by ELISA, normalized to total protein. (C) Representative flow cytometry plots from Live/Dead assay following NLRP3 induction and treatment with NLRP3 Ab–loaded PLL-PS, blank PLL-PS, or untreated healthy cells. (D) Quantification of live cells across treatment groups. Data shown as Mean ± SEM.
Article Snippet: PLL 30KDa (Sigma-Aldrich, P2636); Anti-human IgG AF488 (SoutherenBiotech; 2030-40); Primary human Lung Fibroblasts (ATCC, PCS-201-013); Fibroblast Basal Media (ATCC, PCS-201-030); Fibroblast growth Kit (ATCC, PCS-201-041), NLRP3 Ab (Novus Biologicals; NBP2-12446); Anti mouse Caspase 3 antibody, Anti-Rabbit IgG Cy5 conjugated, MTT assay kit (Invitrogen, V13154), IL-1β Elisa Kit (Invitrogen, DY201-05), DAPI (Invitrogen, D 3571), BCA assay Kit (Thermo Fischer, 23227), Uranyl Acetate, TEM Grid, 300 kDa Float-A-Lyzer (Biotech CE Trial kit dialysis membrane).
Techniques: Enzyme-linked Immunosorbent Assay, Flow Cytometry, Live Dead Assay